Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan October 13, 2026
Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm October 9, 2026 October 9, 2026
Medincell announces the temporary suspension of trading in its shares on Euronext Paris October 9, 2026
Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. Today September 30, 2026 September 30, 2026
Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026 September 21, 2026
Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting September 8, 2026
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg July 28, 2026
